Literature DB >> 33779923

Extracellular Vesicles Contain Putative Cancer Biomarkers.

Sai V Chitti1, Christina Nedeva2.   

Abstract

Emerging evidences have implicated extracellular vesicles (EVs), nanoparticles secreted by cells, in regulating cancer progression. Several seminal studies on EVs have added an additional layer to the previously unanswered questions in understanding the complexity of diseases such as cancer. It has been observed that EV content is highly heterogenous and it likely reflects the dynamic state of the parent cell. Hence, these nano-sized vesicles have been proposed as reservoirs of cancer biomarkers for diagnostic and prognostic purposes. Due to their presence in almost all biological fluids, ability to display membrane, and sometimes cytosolic, cargo of its host cell and increase in their number during disease states has supported the potential utility of EVs as an alternative to current methods of cancer diagnosis. The following chapter will discuss the use of cancer cell-derived EVs as a resource of tumor specific biomarkers for the early diagnosis of disease. In addition, EVs could also be used in personalised medicine as a resource of predictive biomarkers to understand a patient's response to therapy. Overall, EVs could be exploited as a source of cancer biomarkers and could aid in treatment and stratification options to improve patient survival and quality of life.

Entities:  

Keywords:  Biomarkers; Cancer; Disease diagnosis; Extracellular vesicles; Tumor biomarkers

Mesh:

Substances:

Year:  2021        PMID: 33779923     DOI: 10.1007/978-3-030-67171-6_13

Source DB:  PubMed          Journal:  Subcell Biochem        ISSN: 0306-0225


  49 in total

Review 1.  Exosomes in bodily fluids are a highly stable resource of disease biomarkers.

Authors:  Stephanie Boukouris; Suresh Mathivanan
Journal:  Proteomics Clin Appl       Date:  2015-03-19       Impact factor: 3.494

2.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.

Authors:  A A Alizadeh; M B Eisen; R E Davis; C Ma; I S Lossos; A Rosenwald; J C Boldrick; H Sabet; T Tran; X Yu; J I Powell; L Yang; G E Marti; T Moore; J Hudson; L Lu; D B Lewis; R Tibshirani; G Sherlock; W C Chan; T C Greiner; D D Weisenburger; J O Armitage; R Warnke; R Levy; W Wilson; M R Grever; J C Byrd; D Botstein; P O Brown; L M Staudt
Journal:  Nature       Date:  2000-02-03       Impact factor: 49.962

3.  Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.

Authors:  Himisha Beltran; Kenneth Eng; Juan Miguel Mosquera; Alexandros Sigaras; Alessandro Romanel; Hanna Rennert; Myriam Kossai; Chantal Pauli; Bishoy Faltas; Jacqueline Fontugne; Kyung Park; Jason Banfelder; Davide Prandi; Neel Madhukar; Tuo Zhang; Jessica Padilla; Noah Greco; Terra J McNary; Erick Herrscher; David Wilkes; Theresa Y MacDonald; Hui Xue; Vladimir Vacic; Anne-Katrin Emde; Dayna Oschwald; Adrian Y Tan; Zhengming Chen; Colin Collins; Martin E Gleave; Yuzhuo Wang; Dimple Chakravarty; Marc Schiffman; Robert Kim; Fabien Campagne; Brian D Robinson; David M Nanus; Scott T Tagawa; Jenny Z Xiang; Agata Smogorzewska; Francesca Demichelis; David S Rickman; Andrea Sboner; Olivier Elemento; Mark A Rubin
Journal:  JAMA Oncol       Date:  2015-07       Impact factor: 31.777

4.  Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review.

Authors:  Umashankar K Ballehaninna; Ronald S Chamberlain
Journal:  Indian J Surg Oncol       Date:  2011-02-17

Review 5.  [Tumor Marker CA125: biochemical and molecular properties].

Authors:  H Bouanène; A Miled
Journal:  Bull Cancer       Date:  2009-05-12       Impact factor: 1.276

6.  Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior.

Authors:  Shyam K Bandari; Anurag Purushothaman; Vishnu C Ramani; Garrett J Brinkley; Darshan S Chandrashekar; Sooryanarayana Varambally; James A Mobley; Yi Zhang; Elizabeth E Brown; Israel Vlodavsky; Ralph D Sanderson
Journal:  Matrix Biol       Date:  2017-09-06       Impact factor: 11.583

7.  A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.

Authors:  R C Bast; T L Klug; E St John; E Jenison; J M Niloff; H Lazarus; R S Berkowitz; T Leavitt; C T Griffiths; L Parker; V R Zurawski; R C Knapp
Journal:  N Engl J Med       Date:  1983-10-13       Impact factor: 91.245

8.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.

Authors:  Freddie Bray; Jacques Ferlay; Isabelle Soerjomataram; Rebecca L Siegel; Lindsey A Torre; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-09-12       Impact factor: 508.702

9.  Multiplex profiling of serum proteins in solution using barcoded antibody fragments and next generation sequencing.

Authors:  Mattias Brofelth; Anna Isinger Ekstrand; Shashank Gour; Ronnie Jansson; My Hedhammar; Björn Elleby; Anders Kvist; Christer Wingren; Ulrika Axelsson; Carl A K Borrebaeck
Journal:  Commun Biol       Date:  2020-07-03

10.  Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1.

Authors:  Chi Lam Au Yeung; Ngai-Na Co; Tetsushi Tsuruga; Tsz-Lun Yeung; Suet-Ying Kwan; Cecilia S Leung; Yong Li; Edward S Lu; Kenny Kwan; Kwong-Kwok Wong; Rosemarie Schmandt; Karen H Lu; Samuel C Mok
Journal:  Nat Commun       Date:  2016-03-29       Impact factor: 14.919

View more
  1 in total

Review 1.  The Application of Liquid Biopsy Techniques in High-Risk Population for Hepatocellular Carcinoma.

Authors:  Jingnuo Ding; Weifeng Zhao
Journal:  Cancer Manag Res       Date:  2022-09-15       Impact factor: 3.602

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.